Key takeaways
- $22B IQVIA-reported 2023 US type 2 diabetes drug market spend, the top-down anchor for this model
- 38.4M/29.7M estimated US diabetes prevalence and diagnosed patient count, the bottom-up patient base
- $412.9B ADA's 2022 estimate of total US economic cost of diabetes (direct medical costs plus reduced productivity), the broader burden context distinct from the $22B pharmaceutical market
- 41% tirzepatide's share of new GLP-1 starts, a directional class-share signal, not a revenue-share figure
IQVIA's $22B top-down 2023 US T2D drug-spend figure and a 29.7M-diagnosed-patient bottom-up build converge, but the per-class revenue split behind that total is a gap this model names rather than fills with invented numbers.
Two sizing methods anchor this model, and they are deliberately not blended into a single unsourced figure. The top-down method starts from IQVIA's reported 2023 US type 2 diabetes drug market spend of approximately $22 billion, a figure that already nets out the full class mix (metformin, SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, and insulin used in T2D) at the market level. The bottom-up method starts from patient count: an estimated 38.4 million Americans have diabetes, of whom roughly 29.7 million are diagnosed, and applying a treated-patient share against published per-patient pricing across major drug classes produces an independent estimate that lands in a comparable range to the top-down figure.
The broader disease burden puts the $22B drug-spend figure in context rather than inflating it. The American Diabetes Association's 2022 cost-of-diabetes estimate puts total US economic cost, direct medical costs plus reduced productivity, at $412.9 billion, meaning pharmaceutical spend on T2D drugs specifically is a fraction of the disease's total economic footprint. That distinction matters for any sizing exercise: the addressable pharmaceutical market is $22B, not $412.9B, and conflating the two overstates the commercial opportunity by an order of magnitude.
Where this model deliberately stops short is the per-class revenue split within the $22B total. Tirzepatide's 41% share of new GLP-1 starts is a directional signal about where incremental prescribing is going, not a revenue-share figure, since script share and dollar share diverge once list price, rebate depth, and dosing frequency differ across agents. Building a per-class dollar breakdown would require prescription-volume and net-price data this model does not yet have verified; it is flagged here as the specific gap a future update should close, rather than backfilled with an estimate presented as fact.
US type 2 diabetes sizing — top-down drug spend versus bottom-up patient-count build
| Sizing Method | Basis | Estimate / Figure | Source |
|---|---|---|---|
| Top-down (drug spend) | US T2D pharmaceutical market, 2023 | ~$22B | IQVIA |
| Bottom-up (patient count) | Diagnosed patient base × treated share × per-patient pricing | 38.4M prevalence / 29.7M diagnosed | CDC/published diabetes surveillance estimates |
| Disease burden (context, not market size) | Total direct + indirect economic cost, 2022 | $412.9B | American Diabetes Association |
| Class-share directional signal | Share of new GLP-1 starts | Tirzepatide 41% | Published prescribing-trend data |
Sources: IQVIA US pharmaceutical market data, 2023; CDC and published US diabetes prevalence/diagnosis surveillance estimates; American Diabetes Association, Economic Costs of Diabetes in the U.S. in 2022; published GLP-1 new-start prescribing-trend data.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How does IQVIA's $22B top-down 2023 drug-spend figure compare to a bottom-up build from the 38.4M prevalence and 29.7M diagnosed patient base, and where do the two methods converge? • IQVIA top-down methodology and the $22B figure's scope • Bottom-up patient-count-times-pricing build across major T2D drug classes • The triangulation range where both methods agree, and the confidence band around it
- How should the $412.9B ADA total cost-of-diabetes figure be used, and why is it not the addressable pharmaceutical market size? • The distinction between total disease economic burden and pharmaceutical market spend • Why $22B, not $412.9B, is the correct sizing anchor for a drug-focused forecast • Guidance on where the ADA figure is useful context versus where it would overstate opportunity
- What does tirzepatide's 41% share of new GLP-1 starts imply for class-level revenue, and what would it take to build a defensible per-class dollar split? • The distinction between script-share and dollar-share signals • What data (prescription volume, net price by class) is needed to close the per-class revenue gap • This model's explicit flag of that gap as a scoped item for a future update, not an invented figure
What's inside
-
1 · The Binding Constraint 2 pp
- Why triangulating top-down and bottom-up methods, not picking one, is the assumption the rest of the model rests on
- Pressure-tested against the $22B IQVIA figure before the bottom-up build is run
-
2 · Top-Down Sizing — IQVIA Drug Spend 3 pp
- IQVIA's reported $22B 2023 US T2D drug market spend and its class-mix scope
- What the top-down figure includes and excludes
-
3 · Bottom-Up Sizing — Patient Count × Pricing 3 pp
- 38.4M prevalence and 29.7M diagnosed patient base build
- Treated-patient share and per-patient pricing assumptions across major drug classes
-
4 · Disease Burden Context — ADA Total Cost 2 pp
- The $412.9B 2022 ADA total economic cost of diabetes
- Why this is disease burden context, not the addressable pharmaceutical market
-
5 · Triangulation & Confidence Range 3 pp
- Where the top-down and bottom-up methods converge
- Confidence range around the triangulated total
-
6 · Class-Share Directional Signal 2 pp
- Tirzepatide's 41% share of new GLP-1 starts as a script-share, not dollar-share, indicator
- The per-class revenue split flagged as a known gap for a future update
-
7 · Sensitivity Analysis 3 pp
- Which assumption moves the triangulated total most: treated-patient share, per-patient pricing, or class mix
-
8 · Client Alignment Questions 2 pp
- The open sizing questions your team must close before the number is used in planning, including the per-class revenue gap
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom model delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this model
AXLRx delivers cardiometabolic market sizing models built for forecasting and strategy teams sizing the US type 2 diabetes opportunity. Custom model in 72 hours.
- 1. Submit your requestSpecify your indication, market, and cohort or class-level definition.
- 2. Scoping callAXLRx analyst confirms triangulation methods and comparator set, including any per-class revenue scope, before building.
- 3. DeliveryResearch-verified sizing model in 72 hours with optional analyst readout.
How AXLRx builds this model
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx market sizing model triangulates at least two independent methods, here top-down drug spend and bottom-up patient-count, before accepting a market total. This is explicitly a sizing model (static market-spend estimate), distinct from a Pricing Strategy or Patient Flow model.
Type 2 diabetes US sizing sources: IQVIA 2023 US pharmaceutical market data, CDC/published diabetes prevalence and diagnosis surveillance estimates, the American Diabetes Association's 2022 cost-of-diabetes report, and published GLP-1 new-start prescribing-trend data.
- IQVIA's $22B 2023 US T2D drug market spend figure verified against published IQVIA market data
- 38.4M prevalence and 29.7M diagnosed patient figures verified against CDC/published US diabetes surveillance estimates
- The $412.9B ADA total economic cost figure verified against the American Diabetes Association's 2022 cost-of-diabetes report
- Tirzepatide's 41% new-GLP-1-start share verified against published prescribing-trend data; flagged explicitly as a script-share signal, not a revenue-share estimate
Frequently asked questions
Deliverables What formats are included with every model?
Every commissioned Market Sizing Model includes an editable 6-sheet Excel model (Cover, Top-Down Build, Bottom-Up Build, Triangulation, Sensitivity, QC & Sources) and a PDF methodology brief, no PowerPoint deck, since a sizing model is built to be worked in directly rather than presented from. An optional 45-minute analyst readout call is included.
Sources How is the market total verified?
AXLRx triangulates every sizing estimate across at least two independent methods, top-down market spend and bottom-up patient-count, no single-source number ships unverified. Where a figure cannot be independently verified, such as a per-class revenue split, it is flagged as a gap rather than estimated.
Customisation Can I size a specific drug class or sub-segment?
Yes. The intake form captures your indication, target drug class or segment, and cohort definition. A scoping call confirms scope, including whether a per-class revenue build is in scope, before research starts. Commission via the intake form to start.